Cardiff Oncology, Inc. (CRDF)
NASDAQ: CRDF · Real-Time Price · USD
0.81285
-0.0051 (-0.63%)
Jul 29, 2026, 2:48 PM EDT - Market open

Cardiff Oncology Financials Overview

Millions USD. Fiscal year is Jan - Dec.

Revenue & Profits

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
0.530.590.680.490.390.36
Revenue Growth
-10.71%-13.18%39.96%26.42%7.52%-1.91%
Gross Profit
0.530.590.680.490.390.36
Operating Income
-47.43-48.96-48.65-45.41-39.9-28.86
Net Income
-44.79-45.88-45.46-41.47-38.73-28.32
Earnings Per Share
-0.67-0.69-0.95-0.93-0.89-0.73
EPS Growth
------

Cash & Debt

Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Investments
46.0658.391.7574.82105.27140.82
Total Debt
0.650.831.522.152.723.12
Net Cash (Debt)
45.4157.4790.2272.67102.55137.7
Net Cash Growth
-42.18%-36.30%24.15%-29.13%-25.53%5.83%
Net Cash Per Share
0.670.861.891.632.353.53

Cash Flow & CapEx

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Cash Flow
-37.42-37.92-37.69-30.89-33.82-23.04
Capital Expenditures
--0.04-0.08-0.58-1.01-0.21
Free Cash Flow
-37.42-37.97-37.77-31.47-34.83-23.25
Free Cash Flow Growth
------

Margins

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Gross Margin
100.00%100.00%100.00%100.00%100.00%100.00%
Operating Margin
-9033.90%-8256.32%-7123.13%-9305.74%-10337.30%-8037.60%
Pretax Margin
-8526.10%-7732.04%-6651.68%-8492.01%-10026.94%-7880.50%
Profit Margin
-8526.10%-7732.04%-6651.68%-8492.01%-10026.90%-7880.50%
FCF Margin
-7127.05%-6402.53%-5530.45%-6448.57%-9022.28%-6474.93%

Valuation

Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJul '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
PS Ratio
102.27323.67422.72135.50162.04702.52